<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>41(10)</volume><submitter>Dangor Z</submitter><funding>Bill &amp;amp;amp; Melinda Gates Foundation</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Vaccine development for Group B Streptococcus (GBS), a common cause of invasive disease in early-infancy and adverse pregnancy outcomes, include exploring widely-expressed GBS surface proteins as vaccine epitopes. We investigated the association between natural infant serum IgG against the RibN and Alp1N domains and risk of invasive GBS disease caused by isolates expressing these proteins.&lt;h4>Methods&lt;/h4>We analyzed maternal and infant serum samples from GBS disease cases and infants born to GBS-colonized women controls. Bayesian modelling was used to calculate the GBS homotypic IgG concentration associated with risk reduction of invasive disease in the infant.&lt;h4>Results&lt;/h4>PCR-based typing of 85 GBS invasive isolates showed 46 and 24 possessing the gene for Rib and Al</pubmed_abstract><journal>Vaccine</journal><pagination>1679-1683</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9996286</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.</pubmed_title><pmcid>PMC9996286</pmcid><pubmed_authors>Pawlowski A</pubmed_authors><pubmed_authors>Dangor Z</pubmed_authors><pubmed_authors>Fisher PB</pubmed_authors><pubmed_authors>Lala SG</pubmed_authors><pubmed_authors>Izu A</pubmed_authors><pubmed_authors>Johansson-Lindbom B</pubmed_authors><pubmed_authors>Madhi SA</pubmed_authors><pubmed_authors>Kwatra G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.</name><description>&lt;h4>Background&lt;/h4>Vaccine development for Group B Streptococcus (GBS), a common cause of invasive disease in early-infancy and adverse pregnancy outcomes, include exploring widely-expressed GBS surface proteins as vaccine epitopes. We investigated the association between natural infant serum IgG against the RibN and Alp1N domains and risk of invasive GBS disease caused by isolates expressing these proteins.&lt;h4>Methods&lt;/h4>We analyzed maternal and infant serum samples from GBS disease cases and infants born to GBS-colonized women controls. Bayesian modelling was used to calculate the GBS homotypic IgG concentration associated with risk reduction of invasive disease in the infant.&lt;h4>Results&lt;/h4>PCR-based typing of 85 GBS invasive isolates showed 46 and 24 possessing the gene for Rib and Al</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-19T12:37:23.183Z</modification><creation>2025-04-19T12:37:23.183Z</creation></dates><accession>S-EPMC9996286</accession><cross_references><pubmed>36754766</pubmed><doi>10.1016/j.vaccine.2023.01.071</doi></cross_references></HashMap>